



ElectroMAX™ DH5α-E™ Cells

Cat. No. 11319-019

Size: 0.5 ml
Store at -80°C
(Do not store in liquid nitrogen)

Description

ElectroMAX™ DH5α-E™ Cells are *E. coli* cells which can be transformed by electroporation (1,2). These cells can only be transformed by electroporation and are **not** transformed by "heat shock". DH5α-E™ Cells are suitable for the generation of cDNA libraries using pUC or pBR322-derived vectors. The $\phi 80lacZ\Delta M15$ marker provides α -complementation of the β -galactosidase gene allowing blue/white screening on agar plates containing X-gal or Bluo-gal. DH5α-E™ allows efficient transformation of large plasmids and can also serve as a host for M13mp cloning vectors if a lawn of DH5αF™, DH5αF'IQ™, JM101, or JM107 is provided to allow plaque formation. We do not recommend using this strain for direct cloning of methylated genomic DNA.

Component	Amount
DH5α-E™ Cells	5 x 100 μ l
pUC19 DNA (10 pg/ μ l)	50 μ l
S.O.C. Medium	2 x 6 ml

Genotype

F⁻ $\phi 80lacZ\Delta M15 \Delta(lacZYA-argF)$ U169 *deoR recA1 endA1 hsdR17*
(*r_k*⁻, *m_k*⁺) *gal⁻ phoA supE44 λ ⁻ thi⁻¹ gyrA96 relA1*

Quality Control

ElectroMAX™ DH5α-E™ Cells are tested for transformation efficiency using the protocol on the next page and the following electroporator conditions: 2.0 kV, 200 Ω , 25 μ F. Transformation efficiency should be $>1.0 \times 10^{10}$ transformants/ μ g of pUC19 DNA.

Part No. 11319019.pps

Rev. Date: 03/19/03

This product is distributed for laboratory research only. CAUTION: Not for diagnostic use. The safety and efficacy of this product in diagnostic or other clinical uses has not been established.

For technical questions about this product, call the Invitrogen Tech-Line® U.S.A. 800 955 6288

Transformation Procedure

pUC19 control DNA (10 pg/ μ l) is provided to check transformation efficiency. Use experimental DNA that is free of phenol, ethanol, salts, protein, and detergents to obtain maximum transformation efficiency.

1. Add DNA to microcentrifuge tubes.
 - A. To determine transformation efficiency, add 1 μ l of the pUC19 control DNA to a microcentrifuge tube.
 - B. For ligation reactions, precipitate the reactions with ethanol and resuspend in TE Buffer (10 mM Tris HCl, pH 7.5; 1 mM EDTA). The concentration of resuspended DNA should not exceed 100 ng/ μ l. Add 1 μ l of the DNA to a microcentrifuge tube (see Note 1).
2. Thaw ElectroMAX™ DH5 α -E™ cells on wet ice.
3. When cells are thawed, mix cells by tapping gently. Add 20 μ l of cells to each chilled microcentrifuge tube.
4. Refreeze any unused cells in a dry ice/ethanol bath for 5 minutes before returning them to the -80°C freezer. Do not use liquid nitrogen. Although the cells are refreezable, subsequent freeze-thaw cycles will decrease transformation efficiency.
5. Pipette the cell/DNA mixture into a chilled 0.1 cm cuvette and electroporate. If you are using the BTX® ECM® 630 or BioRad GenePulser® II electroporator, we recommend using the following electroporator conditions: 2.0 kV, 200 Ω , 25 μ F (see Note 2).
6. To the cells in the cuvette, add 1 ml of S.O.C. medium and transfer the solution to a 15 ml snap-cap tube (e.g. Falcon™ tube).
7. Shake at 225 rpm (37°C) for 1 hour.

8. Dilute cells transformed with pUC19 control DNA 1:100 with S.O.C. medium. Spread 50 μ l of the dilution on prewarmed LB plates containing 100 μ g/ml ampicillin.
9. Dilute experimental reactions as necessary and spread 100-200 μ l on selective plates.
10. Incubate plates overnight at 37°C.

Growth of Transformants for Plasmid Preparations

Grow ElectroMAX™ DH5 α -E™ Cells which have been transformed with a pUC-based plasmid overnight at 37°C in TB (3). A 100 ml culture in a 500 ml baffled shake flask will yield approximately 1 mg of pUC19 DNA.

Notes

1. Transformation efficiencies will be 10- to 100-fold lower for ligation mixtures and cDNA than for an intact control plasmid such as pUC19. **Salts and buffers severely inhibit electroporation.** Ligation reactions can be diluted 5-fold, and 1 μ l added to 20 μ l of cells. For optimal results, precipitate ligation mixtures with ethanol prior to transformation. Use only 1 to 2 μ l of the resuspended DNA per 20 μ l reaction. Adding undiluted ligation mixtures or too high a volume of DNA decreases transformation efficiency and increases the risk of arcing.
2. If you are using an electroporator other than a BTX® ECM® 630 or BioRad GenePulser® II electroporator, you may need to vary the settings to achieve optimal transformation efficiency.

3. Transformation efficiency (CFU/ μg):

$$\frac{\text{CFU on control plate}}{\text{pg pUC19 DNA}} \times \frac{1 \times 10^6 \text{ pg}}{\mu\text{g}} \times \frac{\text{volume of transformants}}{\text{volume plated}} \times \frac{\text{dilution}}{\text{factor}}$$

For example, if 10 pg of pUC19 yields 50 colonies when 50 μl of a 1:100 dilution is plated, then:

$$\text{CFU}/\mu\text{g} = \frac{50 \text{ CFU}}{10 \text{ pg}} \times \frac{1 \times 10^6 \text{ pg}}{\mu\text{g}} \times \frac{1 \text{ ml}}{0.05 \text{ ml plated}} \times 10^2 = 1.0 \times 10^{10}$$

References

1. Calvin, N. M., and Hanawalt, P. C. (1988) *J. Bacteriol.* 170, 2796.
2. Dower, William J., *et al.* (1988) *Nucl. Acids Research* 16, 6127.
3. Tartof, K. D. and Hobbs, C. A., (1987) *Focus*[®] 9:2, 12.

Limited Use Label License No. 8: *deoR* Cells

This product is the subject of U.S. Patent No. 4,851,348 licensed exclusively to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

©2003 Invitrogen Corporation. All rights reserved.